AU
UK
CA
NZ
IND
US
Wells Fargo raised its price target on Nvidia ($NVDA) to $315 from $265, maintaining its Overweight rating ahead of the company's quarterlyEarningsreport. The revision is grounded in a new capacity-driven model that reflects growing gigawatt-scale data centre buildouts — a shift that underscores just …
Key Highlights
USEquitymarkets remained relatively resilient despite escalating geopolitical uncertainty and rising energy prices, with theDow Jones Industrial Averageadvancing 95.31 points (+0.19%) to 49,704.47, the S&P 500 gaining 13.91 points (+0.19%) to 7,412.84, and theNasdaqComposite rising 27.05 points (+0.10%) to 26,274.13. Investor sentiment continued to be …
Harrow (Nasdaq: HROW) fell 7 per cent to $35.50 in after-hours trading on Tuesday after the ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million — a figure that, on the surface, understates the underlying commercial momentum by the amount of a specific and …
Exagen Inc. (Nasdaq: XGN) surged 35 per cent to close at $3.98 on Tuesday after the medical diagnostics company reported a first quarter that exceeded expectations on the metrics that matter most for a diagnosticsBusinessat this stage of its commercial development: volume, pricing, and …
Liquidia Corporation (Nasdaq: LQDA) delivered one of the most emphatic commercial readouts in the pulmonary hypertension space on Tuesday, sending its shares 25 per cent higher to close at $53.13 as investors digested a first-quarter performance that left little room for equivocation. YUTREPIA, the …
Actuate Therapeutics (Nasdaq: ACTU) closed 10 per cent lower at $2.98 on Tuesday, in what may rank as one of the more counterintuitive market reactions of the session. The company had just announced that the US Food and Drug Administration had cleared its Investigational …
Aditxt, Inc. (NASDAQ: ADTX) closed 8 per cent lower at $0.11 on Tuesday as shareholders absorbed the implications of a Nasdaq Staff Determination letter that brought the company to the edge of a potentially terminal regulatory cliff. The disclosure confirmed what the share price …
Shares in Ensysce Biosciences (Nasdaq: ENSC) closed 9 per cent higher at $0.38 on Tuesday, as the company placed itself at the centre of one of the most consequential debates in contemporary pharmacology: how to engineer effective pain relief without handing patients or recreational …
Please wait processing your request...